Zika virus is an emerging disease that is spread by Aedes mosquitoes. The virus was first isolated in Central Africa, and has since been spread to South Asia and recently to South America. Outbreaks were reported in Micronesia in 2007 and in Brazil in 2015, confirming at least 13 autochthonous infections. The Zika virus outbreak in Brazil in 2016 has gained world-wide attention, and has been linked to an increasing number of microcephaly and Guillain-Barre syndrome cases. In April 2016 the Centers for Disease Control, in the USA, confirmed the link between Zika virus infection of the fetus with microcephaly. Zika virus can cause mild fever, rash, myalgia, arthralgia and headaches, with one in four infected individuals being asymptomatic. Due to similar symptoms Zika virus infected individuals can easily be mis-diagnosed as an infection with other arboviruses, including Dengue, Chikungunya and Oropouche. In addition, Zika virus has been implicated in causing microcephaly through transmission in utero. There is no vaccine or specific treatment available for Zika virus. There is currently a major worldwide effort underway to develop effective diagnostic assays that can both detect Zika virus infection, and distinguish infection from other flaviviruses, especially Dengue virus infection. This purified Zika virus lysate has been prepared to offer a source of a broad range of Zika virus antigens that may be relevant for the detection of Zika virus specific antibodies. This material has been produced by culturing Zika virus in Vero cells.
ELISA analysis using human sera have shown that this lysate is only recognized by anti-Zika IgG and not anti-dengue-IgG antibodies in human serum.
Description:Supernatant of Vero cells infected with Zika virus was harvested 7 days post infection, virions were concentrated and purified by ultracentrifugation. Purified virions were lysed in PBS containing 1% Triton X-100, then heat inactivated at 56°C for 1hr.
Inactivation:Virus could not be cultured from at least 1ul of lysate as determined by Vero infectivity assay. However, lysate should be handled under BSL 2 conditions since the presence of infectious virus cannot be excluded.
Storage and Stability:Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ug
Source Antigen：Vero cells infected with Zika virus
Grade：Purified
Purity：Concentrated from the cell supernatant, purified via sucrose gradient ultracentrifugation, lysed in 1% Triton X-100 and heat inactivated
Form：Supplied as a liquid in DPBS, 1% Triton X-100.
